Compare · ACHV vs CEMI
ACHV vs CEMI
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Chembio Diagnostics Inc. (CEMI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and CEMI operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ACHV carries a market cap of $656.5M.
- ACHV has hit the wire 3 times in the past 4 weeks while CEMI has been quiet.
- ACHV has more recent analyst coverage (11 ratings vs 1 for CEMI).
- Company
- Achieve Life Sciences Inc.
- Chembio Diagnostics Inc.
- Price
- -
- -
- Market cap
- $656.5M
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 0
- Recent ratings
- 11
- 1
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Chembio Diagnostics Inc.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Latest ACHV
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- SEC Form 4 filed by Achieve Life Sciences Inc.
- SEC Form 3 filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update
- Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
- Stifel initiated coverage on Achieve Life Sciences with a new price target
Latest CEMI
- SEC Form 15-12G filed by Chembio Diagnostics Inc.
- SEC Form SC 13D/A filed by Chembio Diagnostics Inc. (Amendment)
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form 4 filed by Angelico Paul
- SEC Form 4 filed by Acheson David
- SEC Form 4 filed by Eberly Richard